Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2023-04-03 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
关于高级管理人员减持股份预披露公告
Director's Dealing Classification · 100% confidence The document is a public announcement regarding a senior management member's plan to reduce (sell) shares of the company. It details the shareholder's identity, shareholding, reasons for reduction, method, timing, quantity, and risk disclosures. There is no financial data, no report attached or referenced as published, and no mention of earnings, annual reports, or other financial statements. The content fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on the share reduction plan by a senior executive, confirming it is a Director's Dealing filing.
2023-04-03 Chinese
监事会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 11th meeting of the 9th Supervisory Board of Dongbei Pharmaceutical Group Co., Ltd. It includes voting results on various proposals related to the company's 2022 annual work report, remuneration, financial statements, profit distribution plan, annual report, internal control self-evaluation, asset impairment provisions, audit firm appointment, credit limits, guarantees, related party transactions, and accounting policy changes. The document references multiple other filings and reports hosted on an external site (巨潮资讯网) but does not itself contain the full reports or financial statements. The document is a formal announcement of meeting resolutions and voting outcomes, which are to be submitted to the 2022 Annual General Meeting for approval. It is not the annual report itself, nor a financial report, but an official disclosure of supervisory board meeting decisions and voting results. Therefore, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3637 characters, which is relatively short and consistent with an announcement rather than a full report.
2023-03-29 Chinese
关于公司2022年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2022 profit distribution plan, including details on proposed cash dividends per share, legal compliance, board and independent directors' opinions, and the need for shareholder approval at the upcoming annual general meeting. It does not contain full financial statements or comprehensive financial performance data but focuses on the dividend proposal and related approvals. The document length is short (2049 characters) and it is clearly an announcement of a profit distribution plan rather than a full annual report or interim report. This fits the category of Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and details for shareholders.
2023-03-29 Chinese
2022年度独立董事述职报告（王国栋）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2022 from a specific independent director of the company. It details the director's attendance at board and shareholder meetings, independent opinions on various company matters, committee work, investigations into company management, and efforts to protect investor rights. The content focuses on governance, oversight, and compliance with laws and regulations, rather than financial results or audit opinions. It is a detailed report on the director's activities and governance role rather than a general management report or financial report. This fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities. The document length is 2826 characters, which is relatively short but contains substantive content about the director's duties and opinions, not just an announcement or certification. Therefore, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2023-03-29 Chinese
独立董事对公司第九届董事会第十五次会议相关事项发表的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on several agenda items for the company's 9th Board of Directors 15th meeting. It references the company's 2022 annual report, profit distribution plan, internal control self-assessment report, audit firm reappointment, and related party transactions. The content is about board-level opinions and approvals rather than the full annual report itself. The document is relatively short (1450 characters) and focuses on governance and board meeting matters. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters, including board meeting opinions and approvals.
2023-03-29 Chinese
关于公司为全资子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Dongbei Pharmaceutical Group Co., Ltd. regarding the provision of guarantees for its wholly-owned subsidiaries. It includes detailed information about the guarantee amounts, the subsidiaries involved, their financial data, and the board's opinions on the guarantees. The document is a formal announcement related to financing activities, specifically about guarantees provided to subsidiaries to support their credit lines and financial needs. There is no indication that this is a full financial report, audit report, or earnings release. It is not a regulatory filing or a report publication announcement since it contains substantive details about the guarantee arrangements. The content fits best under the category of Capital/Financing Update (CAP), as it deals with financing activities and guarantees related to credit facilities.
2023-03-29 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.